In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking ...

Tirzepatide is a long-acting dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist.

Tirzepatide, currently marketed by Eli Lilly (NYSE:LLY) as Mounjaro and Zepbound for diabetes and weight loss, respectively, ...

SUMMT has shown for the first time that a drug can reduce major heart failure clinical outcomes in patients with heart ...

"Obesity contributes to worsening heart failure, and while tirzepatide causes considerable weight loss, research is lacking ...

The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.

CHICAGO -- A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and ...

Detailed results were announced from a phase 3 clinical trial evaluating the use of tirzepatide in adults with heart failure with preserved ejection fraction (HFpEF) and obesity. The multicenter, ...

HF specialists agree these drugs will be key tools in fighting the obesity-related HFpEF epidemic. Hurdles and questions ...

Eli Lilly's tirzepatide cut cardiovascular mortality and heart failure event risk by 38% in HFpEF patients over a two-year ...

This is a strong argument for reimbursement…I think that the GLP-1R agonists, or tirzepatide, will soon enter the guidelines ...

Eli Lilly and Co. (LLY) has released detailed findings from the Phase 3 SUMMIT trial, demonstrating that tirzepatide significantly ...